Cardiff Oncology, Inc. (CRDF) is a Biotechnology company in the Healthcare sector, currently trading at $1.70. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Valuation: CRDF trades at a trailing Price-to-Earnings (P/E) of -2.3 (S&P 500 average ~25).
Financials: revenue is $593,000, +17.7%/yr average growth. Net income is $46M (loss), growing at -7%/yr. Net profit margin is -7736.3% (negative). Gross margin is -52.4% (-100.6 pp trend).
Balance sheet: total debt is $832,000 against $45M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 3.67 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $62M.
Analyst outlook: 8 / 12 analysts rate CRDF as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 55/100 (Partial), Income 10/100 (Fail).
